⁦MPN Voice⁩ @MPNSM great presentation of highlights from ASH so grateful to ⁦Beth Psaila⁩ Jon Lambert and Natalia Curto Garcia for also joining and giving great presentations

Looks like a great meeting really important aspect of disease physiology and treatment dynamics. Looking forward to this for @MPNSM

I am certainly looking forward to this meeting which is always packed with new insights and fun interactions
@MPNSM and all those interested I would encourage you too!

Final weeks!!
The Cancer Tech Accelerator 3.0 is currently open for applications. Blood Cancer UK has joined this innovative funding programme to offer up to £70,000 of funding for research projects in the field of blood cancers. Applications close on 16 February 2024

📣 Empowering strides in Myelofibrosis treatment! 👉🏻 EMA's approval of momelotinib opens new doors of hope. 📲 Join the conversation and explore the impact in our latest news: gmpnsf.org/post/ema-appro…

#MPNsm

Primary or secondary myelofibrosis, does it make a difference?
See our experience Hôpital Saint-Louis AP-HP AP-HP Université Paris Cité AmericanJournalofHematology #MPNsm #CentreIntégréDesNMP

👉 doi.org/10.1002/ajh.27…

📣 #ESHMPN2024 ONLY 3 WEEKS LEFT TO SUBMIT YOUR ABSTRACT!
Proceed now ➡️ bit.ly/3PALAGS
10th Translational Research Conference MYELOPROLIFERATIVE NEOPLASMS
🗓️ April 26-28, 2024 in Mandelieu 🇫🇷
Chairs: J.J. Kiladjian, Ross Levine, Jyoti Nangalia
#ESHCONFERENCES #MPNsm

👉👉👉Please Join us now for #MPNSM Nasyiah Uswatun K seminar and discussion now on live !

J.J. Kiladjian Tania Jain Claire Harrison Naveen Pemmaraju, MD Ruben A. Mesa, MD Mohamad Mohty

bit.ly/48mPRV4

Read about a study that is looking at the epidemiology of Chagas disease in London.

Researchers hope to translate this epidemiological understanding into a screening programme.

local.nihr.ac.uk/news/south-lon…

We’re hosting a Post-ASH Virtual Highlights Series, featuring presentations & discussions on selected abstracts from #ASH23 , w/ leading #HemOnc experts 💻🩸

Join us for our #MPN session, chaired by Claire Harrison

Check out the agenda & REGISTER NOW 👉 vjhemonc.com/feature/post-a…

@MPMSM A peaceful Christmas and a wonderful New Year!

@ASH2023@MPNSM great poster from Patrick Harrington, Andrea Dumenico and the AI / cogstack team from@GSTTnhs highlighting the use of AI and the importance of QRisk 3 in CV risk ⁦Patrick Harrington⁩ congrats team

Naveen Pemmaraju, MD and Raajit Rampal, M.D.Ph.D. threw down the MPN gauntlet at #ASH23 ! Which is the better front line myelofibrosis combination therapy? Aaron Gerds MD, MS Claire Harrison J.J. Kiladjian Prithviraj Bose Stephen Oh Lucia Masarova, MD Brandi Reeves Lindsay Rein Levine Cancer Wake Forest Baptist - Comprehensive Cancer Center

So you went there… which combination is better for front line MF? Pelabresib plus rux or navitoclax plus rux. Vote below

…here is the important point ….a single point change in PGIC correlated with a 1.67 point change in median TSS…. So look at these differences in ph3 data & wider benefits eg anaemia & side effects @MPDRC @MPNSM Naveen Pemmaraju, MD Raajit Rampal, M.D.Ph.D.
& ensure you can give a good rux dose

Yes @ASH23 how about sustainability in healthcare messaging!

Novel “Time Without Transfusion” metric for quantifying the cumulative benefit of anemia in myelofibrosis patients treated with momelotinib: #ASH23 #mpnsm ⁦⁦GSK⁩ ⁦Wake Forest Baptist - Comprehensive Cancer Center⁩ ⁦Levine Cancer⁩ #LevineCancer ⁦Atrium Health⁩ ⁦Atrium HealthWFB⁩

An amazing rare MPN/ mast cell focused session kicking off with the fascinating concept of fedratinib for CNL aCML from Andrew Kuykendall MD @mpnsm

Do join us speaking about about biology and how we can apply this to improve outcomes for our patients! @MPN SM @G_ICEMED

@MPNSM ⁦MPN Voice⁩ ⁦Guy's and St Thomas'⁩ ⁦Guy's and St Thomas' Research⁩ Truly inspirational view from our CRF today am up here working with our team delivering innovative first of a kind therapies for our patients! Well done team!